Ipilimumab/Nivolumab Is the New Standard of Care in Metastatic Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [31] Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma
    Kato, Taigo
    Fujita, Kazutoshi
    Nagahara, Akira
    Nakata, Wataru
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Takada, Shingo
    Nishimura, Kensaku
    Tsujihata, Masao
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    Uemura, Motohide
    Uemura, Hirotsugu
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2023, 34 : S1412 - S1412
  • [32] Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place
    Jurascheck, L.
    Van de Putte, Fransen E.
    Van den Brink, L.
    Van der Mijn, J. C.
    Wilgenhof, S.
    Van Thienen, J. V.
    Haanen, J. B. A. G.
    Boleti, E.
    Powles, T.
    Zondervan, P. J.
    Graafland, N. M.
    Bex, A.
    EUROPEAN UROLOGY, 2024, 85 : S1859 - S1860
  • [33] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma
    Hara, Takuto
    Furukawa, Junya
    Shiraishi, Yusuke
    Okamura, Yasuyoshi
    Bando, Yukari
    Terakawa, Tomoaki
    Harada, Kenichi
    Nakano, Yuzo
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 746 - 752
  • [35] Inferior vena cava thrombectomy following complete response to nivolumab/ipilimumab for metastatic renal cell carcinoma
    Shepherd, Andrew R. H.
    Joshi, Rohit
    Tan, Chuan Ping
    Cohen, Penelope
    Brook, Nicholas R.
    ANZ JOURNAL OF SURGERY, 2020, 90 (7-8) : 1517 - 1519
  • [36] Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report
    Takamatsu, Dai
    Furubayashi, Nobuki
    Negishi, Takahito
    Ieiri, Kosuke
    Inoue, Tomohiro
    Tsukino, Keiji
    Nakamura, Motonobu
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (06) : 590 - 594
  • [37] Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [38] Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
    Gul, Anita
    Stewart, Tyler F.
    Mantia, Charlene M.
    Shah, Neil J.
    Gatof, Emily Stern
    Long, Ying
    Allman, Kimberly D.
    Ornstein, Moshe C.
    Hammers, Hans J.
    McDermott, David F.
    Atkins, Michael B.
    Hurwitz, Michael
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3088 - +
  • [39] A case of novel coronavirus disease after combination therapy with nivolumab and ipilimumab for metastatic renal cell carcinoma
    Kijima, Yu
    Shimizu, Tomokazu
    Kato, Shinya
    Sekido, Eri
    Kano, Kana
    Toguchi, Makoto
    Horiuchi, Toshihide
    Toma, Hiroshi
    Iida, Shoichi
    Takagi, Toshio
    IJU CASE REPORTS, 2022, 5 (02) : 126 - 128
  • [40] Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
    Iinuma, Koji
    Kameyama, Koji
    Kawada, Kei
    Fujimoto, Shota
    Takagi, Kimiaki
    Nagai, Shingo
    Ito, Hiroki
    Ishida, Takashi
    Kawase, Makoto
    Kawase, Kota
    Nakai, Chie
    Kato, Daiki
    Takai, Manabu
    Nakane, Keita
    Koie, Takuya
    CURRENT ONCOLOGY, 2021, 28 (02) : 1402 - 1411
12345